{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T07:58:21Z","timestamp":1764403101495,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Arab Journal of Gastroenterology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ajg.2021.06.001","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T07:45:53Z","timestamp":1631519153000},"page":"285-291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience"],"prefix":"10.1016","volume":"22","author":[{"given":"Gina Gamal","family":"Naguib","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Farid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Elshafie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yehia El","family":"Shazly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Kamal","family":"Shaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitham","family":"Ezzat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eslam","family":"Safwat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ossama Ashraf","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hany","family":"Dabbous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Fouad","family":"Sherief","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Hassany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdy","family":"Elserafy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manal Hamdy","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajg.2021.06.001_b0005","unstructured":"World Health Organization (WHO), Hepatitis C Fact Sheet No164; (updated Jul 2017)."},{"key":"10.1016\/j.ajg.2021.06.001_b0010","unstructured":"Ministry of Health and population [Egypt], El-Zanaty and associates [Egypt], ICF International. Egypt Health Issues Survey 2015. Cairo, Rockville, MD: Ministry of Health and Population, ICF International; 2015."},{"key":"10.1016\/j.ajg.2021.06.001_b0015","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.3390\/cancers12113414","article-title":"Hepatocellular carcinoma risk according to regimens for eradication of hepatitis C virus; interferon or direct acting antivirals","volume":"12","author":"Lee","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ajg.2021.06.001_b0020","doi-asserted-by":"crossref","unstructured":"Hong CM, Liu CH, Su TH, et al. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: real-world data. J Microbiol Immunol Infect, 2020, 53:569-77, pii: S1684-1182(18)30403-1.","DOI":"10.1016\/j.jmii.2018.09.005"},{"key":"10.1016\/j.ajg.2021.06.001_b0025","article-title":"Pre-existing resistance associated polymorphisms to NS3 protease inhibitors in treatment na\u00efve HCV positive Pakistani patients","volume":"15","author":"Khan","year":"2020","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ajg.2021.06.001_b0030","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bjid.2018.04.003","article-title":"Effectiveness and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil","volume":"22","author":"Ferreira","year":"2018","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.ajg.2021.06.001_b0035","unstructured":"Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol, 2017, 2:161-76."},{"key":"10.1016\/j.ajg.2021.06.001_b0040","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/jgh.13912","article-title":"Real-world effectiveness and safety of paritaprevir\/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan","volume":"33","author":"Liu","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ajg.2021.06.001_b0045","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/jvh.12668","article-title":"National treatment programme of hepatitis C in Egypt: hepatitis C virus model of care","volume":"24","author":"El-Akel","year":"2017","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.ajg.2021.06.001_b0050","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.cgh.2017.02.020","article-title":"Real-world effectiveness and safety of oral combination antiviral therapy for hepatitis C virus Genotype 4 infection","volume":"15","author":"Crespo","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ajg.2021.06.001_b0055","first-page":"1","article-title":"An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens","volume":"24","author":"El Kassas","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ajg.2021.06.001_b0060","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3851\/IMP3117","article-title":"Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients","volume":"22","author":"Backus","year":"2017","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ajg.2021.06.001_b0065","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/j.gastro.2016.05.049","article-title":"Effectiveness of sofosbuvir, Ledipasvir\/Sofosbuvir, or Paritaprevir\/Ritonavir\/Ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs national health care system","volume":"151","author":"Ioannou","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajg.2021.06.001_b0070","doi-asserted-by":"crossref","unstructured":"H\u00f6ner Zu Siederdissen C, Buggisch P, B\u00f6ker K, et al. Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting. U Eur Gastroenterol J, 2018, 6:213-24.","DOI":"10.1177\/2050640617716607"},{"key":"10.1016\/j.ajg.2021.06.001_b0075","doi-asserted-by":"crossref","first-page":"9616234","DOI":"10.1155\/2018\/9616234","article-title":"Sofosbuvir plus daclatasvir in treatment of chronic hepatitis C Genotype 4 infection in a cohort of Egyptian patients: an experiment the size of Egyptian village","volume":"2018","author":"Ahmed","year":"2018","journal-title":"Int J Hepatol"},{"key":"10.1016\/j.ajg.2021.06.001_b0080","doi-asserted-by":"crossref","unstructured":"Ahmed OA, Elsebaey MA, Fouad MHA, et al. Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection. Infect Drug Resist, 2018, 11:441-5. Published.","DOI":"10.2147\/IDR.S160593"},{"issue":"Suppl. 2","key":"10.1016\/j.ajg.2021.06.001_b0085","doi-asserted-by":"crossref","first-page":"S222","DOI":"10.1016\/S0168-8278(16)00196-3","article-title":"No effect of proton pump inhibitor (PPI) use on SVR with ledipasvir\/sofosbuvir (LDV\/SOF): real world data from 2034 genotype 1 patients in the Trio network","volume":"64","author":"Afdhal","year":"2016","journal-title":"J Hepatol"},{"issue":"Suppl. 2","key":"10.1016\/j.ajg.2021.06.001_b0090","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1016\/S0168-8278(16)00188-4","article-title":"Effectiveness and safety of sofosbuvir\/ledipasvir treatment for monoinfected genotype 1 HCV patients in real-life clinical practice: results from Spanish hepa-C cohort","volume":"64","author":"Crespo","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajg.2021.06.001_b0095","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/apt.13696","article-title":"Comparative effectiveness of ledipasvir\/sofosbuvir\u00b1ribavirin vs. ombitasvir\/paritaprevir\/ritonavir+ dasabuvir\u00b1ribavirin in 6961 genotype 1 patients treated in routine medical practice","volume":"44","author":"Backus","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl. 2","key":"10.1016\/j.ajg.2021.06.001_b0100","doi-asserted-by":"crossref","first-page":"S797","DOI":"10.1016\/S0168-8278(16)01556-7","article-title":"Effectiveness of Ledipasvir\/Sofosbuvir and Ombitasvir\/Paritaprevir\/Ritonavir\/Dasabuvir in Treatment-na\u00efve and \u2013experienced US veterans with genotype 1 Hepatitis C infection","volume":"64","author":"Fuchs","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajg.2021.06.001_b0105","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/IDR.S153060","article-title":"Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection","volume":"11","author":"Ahmed","year":"2018","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.ajg.2021.06.001_b0110","unstructured":"Tada T, Kumada T, Okushin H, et al. Real-world virological efficacy and safety of ledipasvir and sofosbuvir in patients with chronic hepatitis C virus Genotype 2 infection: A multicenter study. Infect Dis Ther, 385."},{"issue":"Suppl. 2","key":"10.1016\/j.ajg.2021.06.001_b0115","doi-asserted-by":"crossref","first-page":"S218","DOI":"10.1016\/S0168-8278(16)00189-6","article-title":"Effectiveness and safety of ombitasvir, paritaprevir, ritonavir and dasabuvir patients with genotype 1 chronic hepatitis C virus infection: results from Spanish real world cohort","volume":"64","author":"Calleja","year":"2016","journal-title":"J Hepatol"},{"issue":"Suppl. 2","key":"10.1016\/j.ajg.2021.06.001_b0120","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1016\/S0168-8278(16)00187-2","article-title":"Analysis of the real-world effectiveness of direct acting antivirals treatments of hepatitis C in a large population","volume":"64","author":"McCombs","year":"2016","journal-title":"J Hepatol"},{"issue":"Suppl. 2","key":"10.1016\/j.ajg.2021.06.001_b0125","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1016\/S0168-8278(16)01664-0","article-title":"Real-world safety and effectiveness of ombitasvir\/paritaprevir with dasabuvir and\/or ribavirin in the German hepatitis C registry","volume":"64","author":"Hinrichsen","year":"2016","journal-title":"J Hepatol"},{"issue":"Suppl. 2","key":"10.1016\/j.ajg.2021.06.001_b0130","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1016\/S0168-8278(16)00200-2","article-title":"Evidence of impressive real world SVR from the Portuguese ledipasvir\/sofosbuvir and Sofosbuvir Universal Coverage Program to eradicate (eliminate) hepatitis C","volume":"64","author":"Rodrigues","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajg.2021.06.001_b0135","doi-asserted-by":"crossref","unstructured":"Hong CM,Liu CH,Su TH et al. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: real-world data. J Microbiol Immunol Infect, 2020, pii: S1684-1182(18)30403-1, 53:569-77.","DOI":"10.1016\/j.jmii.2018.09.005"},{"key":"10.1016\/j.ajg.2021.06.001_b0140","first-page":"17","article-title":"Hepatitis C infection in Egypt: prevalence, impact and management strategies","volume":"9","author":"Gomaa","year":"2017","journal-title":"Hepat Med"},{"key":"10.1016\/j.ajg.2021.06.001_b0145","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00239-003-2541-3","article-title":"Exponential spread of hepatitis C virus genotype 4a in Egypt","volume":"58","author":"Tanaka","year":"2004","journal-title":"J Mol Evol"},{"key":"10.1016\/j.ajg.2021.06.001_b0150","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1086\/315786","article-title":"Genetic epidemiology of hepatitis C virus throughout Egypt","volume":"182","author":"Ray","year":"2000","journal-title":"J Infect Dis"},{"issue":"e10069","key":"10.1016\/j.ajg.2021.06.001_b0155","article-title":"The effect of Peginterferon Alpha-2a vs. peginterferon Alpha-2b in treatment of naive chronic HCV Genotype-4 patients: a single centre Egyptian study","volume":"13","author":"El Raziky","year":"2013","journal-title":"Hepat Mon"}],"container-title":["Arab Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1687197921000435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1687197921000435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:44:29Z","timestamp":1761659069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1687197921000435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1687197921000435"],"URL":"https:\/\/doi.org\/10.1016\/j.ajg.2021.06.001","relation":{},"ISSN":["1687-1979"],"issn-type":[{"type":"print","value":"1687-1979"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience","name":"articletitle","label":"Article Title"},{"value":"Arab Journal of Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajg.2021.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Pan-Arab Association of Gastroenterology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}